Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PLX038

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ProLynx

Drug class:

Topoisomerase I inhibitor, DDR enhancer

Related drugs:

irinotecan liposomal (0)

topotecan episcleral (0)

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

datopotamab deruxtecan (11)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	rucaparib + PLX038 Sensitive: C4 – Case Studies rucaparib + PLX038 Sensitive : C4	rucaparib + PLX038 Sensitive: C4 – Case Studies rucaparib + PLX038 Sensitive : C4
ATM deletion	Solid Tumor	ATM deletion	Solid Tumor	PLX038 Sensitive: D – Preclinical PLX038 Sensitive : D	PLX038 Sensitive: D – Preclinical PLX038 Sensitive : D
BRCA1 deletion	Solid Tumor	BRCA1 deletion	Solid Tumor	PLX038 Sensitive: D – Preclinical PLX038 Sensitive : D	PLX038 Sensitive: D – Preclinical PLX038 Sensitive : D